PhysioSense AI conducted a small retrospective study examining vascular state before and after administration of a vasodilator using a non-invasive PPG signal.

PhysioSense transforms physiological waveform data into interpretable health and performance insight. We work with signals such as PPG, ECG, arterial pressure waveforms, and related sensor streams to derive richer physiological information than conventional vital signs alone typically provide. Our approach is designed to help partners extract more value from signals they already collect across medical devices, wearables, clinical monitoring systems, and research platforms. PhysioSense supports applications across digital health, clinical monitoring, translational research, and advanced sensing programs. Current areas of work include vascular and hemodynamic interpretation, physiological state tracking, waveform-derived biomarker exploration, and partner-tailored software integration. Representative use cases include early instability detection, post-acute monitoring, treatment-response tracking, chronic cardiovascular and renal risk monitoring, and research programs focused on shock, hemorrhage, sepsis, burns, and neurovascular change. Our team brings experience spanning physiological signal processing, AI/ML, FDA-regulated medical device development, large human studies, and healthcare product strategy. Company leadership has contributed to 30+ products, 10 patents, and programs involving organizations such as the University of Washington, the University of British Columbia, Amgen, Medtronic, Quidel, Kaiser Permanente, Avery Dennison/Vancive Medical, and U.S. Army-funded research. PhysioSense collaborates with device companies, digital health platforms, health organizations, research groups, and innovation partners seeking new ways to interpret physiological signals and build differentiated products or programs.